Man Group plc Invests $78.75 Million in Insulet Corporation $PODD

Man Group plc bought a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 517,217 shares of the medical instruments supplier’s stock, valued at approximately $78,746,000.

A number of other hedge funds have also added to or reduced their stakes in PODD. BlackRock Inc. bought a new stake in Insulet during the 2nd quarter worth about $1,018,582,000. State Street Corp grew its holdings in shares of Insulet by 2.1% in the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after acquiring an additional 65,317 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Insulet by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after acquiring an additional 41,019 shares in the last quarter. Invesco Ltd. increased its position in shares of Insulet by 10.5% in the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after acquiring an additional 141,167 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after acquiring an additional 1,011,369 shares during the last quarter.

Key Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet CEO Ashley McEvoy purchased 1,100 shares at an average price of $147.47, an investment of approximately $162,200. The purchase increased her direct holdings by about 5% and may signal management confidence following the stock’s substantial decline. Insulet CEO share purchase
• Positive Sentiment: Recent operating results remain a support: Insulet’s latest quarterly report exceeded analyst expectations for both earnings and revenue, with revenue rising 23.5% year over year and margins improving. The company’s growth outlook, however, has been reset, making execution key to the investment case.
• Neutral Sentiment: Reported short-interest data shows zero shares short and a zero-day short-interest ratio, but the stated month-over-month change is “NaN,” indicating the data is likely incomplete or erroneous. It should not be interpreted as evidence of a meaningful short-covering or short-selling trend.
• Negative Sentiment: Pomerantz announced that a securities class action has been filed in federal court against Insulet and certain officers. The proposed class covers investors who purchased securities from February 21, 2025, through May 26, 2026, and alleges violations of federal securities laws. The allegations have not been proven. Pomerantz class action announcement
• Negative Sentiment: Several firms issued substantially similar notices encouraging investors to seek lead-plaintiff status by August 31. The claims center on alleged manufacturing deficiencies and two voluntary corrections or recalls affecting millions of Omnipod devices, as well as assertions that Insulet overstated manufacturing quality and growth prospects. The volume of legal announcements increases reputational, litigation-cost, and potential-liability concerns, even though the notices themselves do not establish wrongdoing.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Sanford C. Bernstein dropped their target price on Insulet from $200.00 to $175.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft started coverage on Insulet in a research report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 price target on the stock. Jefferies Financial Group dropped their price objective on Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Canaccord Genuity Group cut their price objective on Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Finally, Weiss Ratings cut shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, June 24th. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Insulet has a consensus rating of “Hold” and a consensus target price of $195.40.

Insider Transactions at Insulet

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.36% of the stock is owned by company insiders.

Insulet Trading Down 1.6%

Shares of PODD stock opened at $143.05 on Wednesday. The firm has a 50 day moving average price of $154.52 and a two-hundred day moving average price of $182.80. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $9.92 billion, a PE ratio of 26.74, a price-to-earnings-growth ratio of 1.15 and a beta of 1.10. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The company had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business’s revenue was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, analysts predict that Insulet Corporation will post 6.51 earnings per share for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.